title: [Studying the tumor growth inhibitory effect of modified GnRH-III-anthracycline bioconjugates in subcutaneous vs. orthotopic models in vivo].
abstract: Targeted tumor therapy is a perspective procedure to specifically destroy the cancer tissues with eliminating or at least decreasing the side effects of anticancer drugs. For this purpose the drug molecule is attached to a targeting moiety (e.g. peptide hormones) that recognizes tumor specific or overexpressed receptors on cancer cells. The in vitro cytostatic or cytotoxic assays do not give proper information whether the tumor growth inhibitory effect of the conjugate is better than the activity of the free drug. Only in vivo studies are adequate to answer this question. However, the selection of the appropriate tumor model is important to eliminate the false positive results. In our studies a gonadotropin-releasing hormone analog (GnRH-III) was applied as targeting moiety in drug conjugates. The in vivo antitumor activity of these conjugates was investigated on mice bearing subcutaneously or orthotopically szigdeveloped tumors. The subcutaneously implanted tumor model which is isolated from its surroundings may provide false results in tumor growth inhibition. In contrast, the orthotopically developed tumor is a better model representing appropriate anatomical and clinical status of cancer. Therefore, the orthotopical colon cancer developed in our laboratory is a suitable model for the study of the antitumor activity of the conjugates prepared for targeted tumor therapy.
authors.affiliation: Biokémiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. kapuvari.bence@oncol.hu.
authors.forename: Bence
authors.initials: B
authors.lastname: Kapuvári
authors.affiliation: Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
authors.forename: Ákos
authors.initials: Á
authors.lastname: Schulcz
authors.affiliation: Peptidkémiai Kutatócsoport, ELTE-MTA, Budapest, Hungary.
authors.forename: Rózsa
authors.initials: R
authors.lastname: Hegedüs
authors.affiliation: Peptidkémiai Kutatócsoport, ELTE-MTA, Budapest, Hungary.
authors.forename: Ildikó
authors.initials: I
authors.lastname: Szabó
authors.affiliation: Zukunftskolleg, University of Konstanz, Department of Chemistry, Konstanz, Germany.
authors.forename: Marilena
authors.initials: M
authors.lastname: Manea
authors.affiliation: Biokémiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. kapuvari.bence@oncol.hu.
authors.forename: Borbála
authors.initials: B
authors.lastname: Vincze
authors.affiliation: Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
authors.forename: József
authors.initials: J
authors.lastname: Tóvári
authors.affiliation: Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Gacs
authors.affiliation: Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
authors.forename: Miguel
authors.initials: M
authors.lastname: Tejeda
authors.affiliation: Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
authors.forename: Dezsõ
authors.initials: D
authors.lastname: Gaál
authors.affiliation: Peptidkémiai Kutatócsoport, ELTE-MTA, Budapest, Hungary.
authors.forename: Gábor
authors.initials: G
authors.lastname: Mezõ